Business
bioAffinity Technologies Announces Sheila Habib, MD and David Hill, MD Join the Company’s Scientific and Medical Advisory Board
SAN ANTONIO--(BUSINESS WIRE)-- bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and
About this update from Bioaffinity Technologies, Inc.
[{"type":"text","content":" SAN ANTONIO--(BUSINESS WIRE)--\nbioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced Sheila Habib, MD, Director of Pulmonary Lung Nodule Clinic and the Lung Cancer Screening Program at the South Texas Veterans Health Care Systems’ Audie L. Murphy Memorial Veterans Hospital, and David Hill, MD, National Board Member of the American Lung Association and assistant clinical professor of medicine at Yale University School of Medicine, have joined the Company’s Scientific and Medical Advisory Board.\n\n“Dr. Habib and Dr. Hill will join other members of our Scientific and Medical Advisory Board who provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics, including CyPath® Lung, a non-invasive test for the early detection of lung cancer,” bioAffinity President and CEO Maria Zannes said. “The caliber of the physicians and researchers who accepted our invitation to join our Scientific and Medical Advisory Board will accelerate the work of our own scientists to bring breakthrough technology to the early diagnosis of cancer.”\n\n“Dr. Hill and Dr. Habib will join other recognized leaders in the lung cancer field who are deeply involved in screening and early diagnosis when treatment options offer the best potential outcome,” said bioAffinity’s Chief Science and Medical Officer and Executive Vice President, Vivienne Rebel, MD, PhD. “We believe their groundbreaking work complements our mission to provide innovative products that have the potential to save thousands of lives every year.”\n\n“Studies show that lung and bronchus cancers represent 20% of all cancers among our veteran population,” said Dr. Habib who is also an Assistant Professor at the University of Texas Health Science Center at San Antonio who specializes in pulmonary nodule management and lung cancer. “We also know that lung cancer is difficult to detect in its early stages and by the time our patients are symptomatic, treatment options are not as effective. A non-invasive, highly accurate and relatively low-cost assay like CyPath can change the paradigm for the diagnosis and treatment of lung cancer not just for veterans but for all patients.”\n\n\"bioAffinity's test using fluorescence technology is a unique approach which can lead to earlier lung cancer diagnosis with better outcomes, while avoiding t...